Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial is a research paper published in Journal of Allergy and Clinical Immunology (2020). On theSindex it has a DataRank of 5.2. It has been cited 164 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.766
From this paper's citation signal
Citation Network Contribution
4.4
From 76 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCATS NIH HHS
Grant: UL1 TR001102
BioCryst Pharmaceuticals, Inc
Harvard Catalyst/The Harvard Clinical and Translational Science Center
National Center for Advancing Translational Sciences, National Institutes of Health
National Center for Research Resources
At Harvard Medical School
FWCI
9.32
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema
Additional file 2 of An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema
Additional file 1 of A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis
Additional file 1 of A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis
Additional file 1 of An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema
Additional file 1 of An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema